Physiological effects of caffeine, epigallocatechin-3-gallate, and exercise in overweight and obese women.
The aim of this study was to evaluate the combined effects of a 10-week exercise program with ingestion of caffeine and epigallocatechin-3-gallate (EGCG) on body composition, cardiovascular fitness, and strength in overweight and obese women. In a double-blind, placebo-controlled approach, overweight and obese women (n = 27) were randomly assigned to treatment groups with exercise (an active-supplementing group with exercise (EX-Act) and a placebo group with exercise (EX-PL)) or without exercise (an active-supplementing group without exercise (NEX-Act) and a placebo group without exercise (NEX-PL)). All participants consumed 1 drink per day for 10 weeks; EX-Act and EX-PL participated in a concurrent endurance and resistance training program. Changes in body composition were assessed using a 4-compartment model. Changes in muscle mass (MM) were evaluated using a DXA-derived appendicular lean-soft tissue equation. There was a significant time × treatment interaction for MM (p = 0.026) and total cholesterol (TC) (p = 0.047), and a significant time × training interaction for peak oxygen consumption (p = 0.046) and upper-body and lower-body strength (p < 0.05). Significant differences between the EX groups and NEX groups for percentage change in MM and peak oxygen consumption, and upper-body and lower-body strength, were revealed. Clinical markers for hepatic and renal function revealed no adverse effects. TC significantly decreased for the active-supplementing groups (EX-Act, NEX-Act). The current study suggests that implementing a caffeine-EGCG-containing drink prior to exercise may improve MM, fitness, and lipid profiles in overweight women.
Department of Health and Exercise Science, University of Oklahoma, 1401 Asp Avenue, Norman, OK 73019, USA.
Abbie E
AE
Smith
Christopher M
CM
Lockwood
Jordan R
JR
Moon
Kristina L
KL
Kendall
David H
DH
Fukuda
Sarah E
SE
Tobkin
Joel T
JT
Cramer
Jeffrey R
JR
Stout
D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage; D001823:Body Composition / Q000187:drug effects; D002110:Caffeine / Q000008:administration & dosage*; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003131:Combined Modality Therapy; D015444:Exercise / Q000502:physiology*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage; D010807:Physical Endurance / Q000187:drug effects*; D010809:Physical Fitness / Q000502:physiology; D055815:Young Adult
D000975:Antioxidants; D008055:Lipids; D010726:Phosphodiesterase Inhibitors; D002110:Caffeine; D002392:Catechin; C045651:epigallocatechin gallate